Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med Firdapse, Catalyst Pharmaceutical has repeatedly emerged triumphant over its d | Thanks to a new settlement with Catalyst,

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva (TEVA) that would delay the launch of a generic version of its drug Firdapse until at least 2035.